SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-24-000269
Filing Date
2024-01-05
Accepted
2024-01-05 16:46:27
Documents
17
Period of Report
2023-12-29
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tenx_8k.htm   iXBRL 8-K 29551
2 CERTIFICATE tenx_ex31.htm EX-3.1 10146
3 PRESS RELEASE tenx_ex991.htm EX-99.1 11840
9 tenx_ex991img2.jpg GRAPHIC 5001
  Complete submission text file 0001654954-24-000269.txt   193495

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tenx-20231229.xsd EX-101.SCH 5720
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20231229_lab.xml EX-101.LAB 15214
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20231229_cal.xml EX-101.CAL 898
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20231229_pre.xml EX-101.PRE 9640
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20231229_def.xml EX-101.DEF 2099
11 EXTRACTED XBRL INSTANCE DOCUMENT tenx_8k_htm.xml XML 3724
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 24516856
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)